Psilocybin versus escitalopram for major depressive disorder: comparative mechanisms

Imperial College Joint Research Compliance Office (JRCO)0 个研究点目标入组 59 人开始时间: 2018年9月10日最近更新: 2022年8月5日

试验速览

2018 Interim results article in https://pubmed.ncbi.nlm.nih.gov/29119217/ (added 28/06/2022) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33852780/ (added 28/06/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35411074/ Increased global integration in the brain after psilocybin therapy for depression (added 28/06/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35431912/ Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression (added 28/06/2022)

•1. Current or previously diagnosed psychotic disorder
•2. Immediate family member with a diagnosed psychotic disorder
•3. Medically significant condition rendering unsuitability for the study (e.g. diabetes, epilepsy, severe cardiovascular disease, hepatic or renal failure e.g. CLRC < 30 ml/min etc)
•4. History of serious suicide attempts requiring hospitalisation.
•5. Significant history of mania (determined by study psychiatrist and medical records)
•6. Psychiatric condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin (e.g. borderline personality disorder)
•7. Blood or needle phobia
•8. Positive pregnancy test at screening or during the study, women who are planning a pregnancy and/or women who are nursing/breastfeeding.
•9. Participants who do not agree to use an acceptable contraceptive method throughout their participation in study.
•10. Current drug or alcohol dependence
•11. No email access
•12. Use of contraindicated medication
•13. Patients presenting with abnormal QT interval prolongation at screening or with a history of this (QTc at screening above 440ms for men and above 470ms for women)

发起方

Imperial College Joint Research Compliance Office (JRCO)